FMO6P and Parkinson disease: Although a few differentially methylated CpGs that showed opposite direction of effect in one disease compared to the other were identified, such as FMO6P and OR51A7, in MSA compared to PD, in most cases, dysregulation was still observed with the CpG in all three disease groups.